Switzerland approves its first protein-based Covid vaccine

SwissInfo

15 April 2022 - Swissmedic announced its approval on Wednesday making Nuvaxovid the first protein-based vaccine to be licensed in Switzerland. 

The American biotech firm Novavax had applied for approval on February 14 through Swiss partner Future Health Pharma.

Read SwissInfo article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Vaccine , Switzerland , COVID-19